Navigation Links
Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
Date:9/3/2008

Helping to Improve Patient Safety, Operational Efficiency Through Bar-Coded

Medication Products and Services

WOBURN, Mass., Sept. 3 /PRNewswire/ -- Safecor Health, LLC, a pharmacy services and unit-dose bar-code repackaging provider to hospitals, health systems and long-term care pharmacies, announced today it has acquired the assets of privately held Regional Service Center, Inc. Both companies are based in Woburn, Massachusetts. Terms of the agreement were not disclosed.

A pioneer of unit-dose and bar-coded medications, Regional Service Center, or RSC, (http://www.unit-dose.com) was launched 30 years ago, and today is the leader in its field. RSC serves more than 350 U.S. hospitals and long-term care pharmacies in more than 30 states and the District of Columbia.

"RSC has an experience base and reputation for quality and customer service that is unmatched in the industry," said Stephen Fischbach, Safecor Health's president and chief executive officer. "We are looking forward to building on RSC's success by investing in capabilities that can play a critical role in the safety of medication administration."

"Bar-coded pharmaceuticals in ready-to-administer doses are an important step in eliminating medication errors while improving the efficiency of pharmacy operations," said Ryan O'Dell, chief marketing and sales officer for Safecor Health. "Hospitals, group purchasing organizations and other sites of care are increasingly outsourcing their packaging operations to us. Having a trusted source for bar-coded medications allows health professionals to focus on other important aspects of their patient safety and bedside-scanning initiatives."

"RSC has served a tremendous customer need and grown successfully over the last three decades," said Robert Crisafi, Ph.D., founder and president of RSC. "Safecor Health shares our passion for quality, superior custome
'/>"/>

SOURCE Safecor Health, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... a timely and reliable way to obtain enough raw ... the tissue they need to build. In a new ... viscosity, and other mechanical properties of adult stem cells ... whether they will turn into bone, cartilage, or fat. ... of extracting the needed cells from a larger and ...
(Date:5/21/2012)... Elsevier,s Computers & Graphics announces the upcoming ... which will incorporate the Collage Authoring Environment, a workflow ... of the 2011 Executable Paper Grand Challenge. The call ... Eurographics 2012 on May 13, during the 3DOR Workshop. ... to embed chunks of executable code and data into ...
(Date:5/21/2012)... International scientific and government experts held a ... use of Oxitec,s genetically modified Aedes aegypti ... Panama. The independent forum was co-organised by ... Institute for Health Studies and the University of Panama. ... institutes as well as the Pan American Health Organisation, ...
(Date:5/18/2012)...  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that ... CEO, will be presenting at the Seventh Annual ... (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The title ... Offer Attractive Targets for Active and Passive Immunotherapy." ... at the Intercontinental Hotel in Boston from 10:15-11:30 ...
Breaking Biology Technology:Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3
... On January 7,2008, Signalife received a deficiency letter ... it advised that Signalife would need to,comply with ... listing under AMEX Rules 1003(a)(iii). This notification was,triggered ... less than,$50 million, which previously exempted Signalife from ...
... New Agent for CLL Patients Approved by the FDA ... Cephalon, Inc. (Nasdaq:,CEPH) today announced that the U.S. Food ... Injection for the,treatment of patients with chronic lymphocytic leukemia ... American Cancer Society,estimates that more than 15,000 new cases ...
... study setup and launch..., WAYLAND, Mass., March ... clinical trials software, announces the,launch of its Trident ... unique parameter driven + custom pluggable design,leaps ahead ... a new era,of needed scalability, productivity, and ease-of-use ...
Other Biology Technology:AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 3Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 4Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 5Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3
(Date:5/21/2012)... University of Singapore,s (NUS) Department of Biological Sciences and ... a compound that is undergoing preclinical trials as a ... and stop them from growing into a tumour. This ... the first time a research group has provided evidence ... , Building on the new findings, the NUS team ...
(Date:5/21/2012)... teams of Australian and US scientists has found there ... Antarctic Bottom Water found off the coast of Antarctica.,Comparing ... Southern Ocean marine science voyage to historical data dating ... much as a 60 per cent reduction in the ... that drives global ocean currents. , In an intensive ...
(Date:5/20/2012)... (HDAC) inhibitor panobinostat is able to target and ... study published in BioMed Central,s open access journal ... University Health Sciences Center have shown that panobinostat ... reduce tumor growth in mice. , Approximately 15% ... be triple negative. These aggressive tumours are missing ...
Breaking Biology News(10 mins):Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2San Diego State Offers Project Management Programs Beginning in January 61681 1San Diego State Offers Project Management Programs Beginning in January 61681 2Hobbits are a new human species according to the statistical analysis of fossils 10800 1Hobbits are a new human species according to the statistical analysis of fossils 10800 2Marrone Bio Innovations Named an IC20 Company 14914 1Marrone Bio Innovations Named an IC20 Company 14914 2
... Institute on Drug Abuse (NIDA), part of the National ... genes that might increase a person’s ability to abstain ... George Uhl at NIDA’s Intramural Research Program and a ... for Nicotine and Smoking Cessation Research at Duke University ...
... MIT have created an ocean model so realistic that the ... in population patterns that precisely mimic their real-world counterparts. , ... the vast diversity of the invisible forests living in our ... half the oxygen we breathe on Earth. And it does ...
... of millipede was recently discovered by a Northern Arizona ... researcher. , J. Judson Wynne, with the Department ... with the U.S. Geological Survey's Southwest Biological Center, and ... of Land Management (BLM), collected specimens leading to the ...
Other Biology News:NIDA study identifies genes that might help some people abstain from smoking 2MIT's ocean model captures diversity of underwater forests 2MIT's ocean model captures diversity of underwater forests 3Discovery of new cave millipedes casts light on Arizona cave ecology 2Discovery of new cave millipedes casts light on Arizona cave ecology 3